(Q27852494)

13 November 2016

title

ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis (English)

1 reference

PubMed

PubMed publication ID

13 November 2016

5

Andreas von Deimling

0 references

Benedikt Wiestler

1

Benedikt Wiestler

0 references

Michael Weller

8

Michael Weller

0 references

Wolfgang Wick

9

Wolfgang Wick

0 references

David Capper

2

David Capper

0 references

Andrey Korshunov

4

Andrey Korshunov

0 references

Stefan M. Pfister

6

Stefan Michael Pfister

0 references

author name string

Tim Holland-Letz

3

0 references

Michael Platten

The chromatin remodelling factor dATRX is involved in heterochromatin formation

7

0 references

publication date

September 2013

0 references

published in

Acta Neuropathologica

0 references

volume

126

0 references

issue

3

0 references

page(s)

443-51

0 references

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1156-Z

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1156-Z

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1156-Z

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1156-Z

Altered telomeres in tumors with ATRX and DAXX mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1156-Z

K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1156-Z

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1156-Z

Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1156-Z

Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1156-Z

Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1156-Z

Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1156-Z

The 2007 WHO classification of tumours of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1156-Z

Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1156-Z

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1156-Z

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1156-Z

Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1156-Z

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1156-Z

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1156-Z

Altered PTEN, ATRX, CHGA, CHGB, and TP53 expression are associated with aggressive VHL-associated pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1156-Z

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1156-Z